InnoCare Pharma Limited, a Hong Kong-listed Chinese biopharma company, said that at least five of the company's innovative drug products are expected to get approved and enter the market in three to four years.

Also, up to four of such new drug products will enter the international market, said Cui Jisong, cofounder, chairman and CEO of InnoCare, in an interview with China Daily at the Zhongguancun Forum - a tech event in Beijing - on Saturday.

"We now have 13 innovative drugs in clinical stages, with over 30 clinical trials underway in China and globally. We hope to accelerate the development of highly promising innovative therapies for global cancer and autoimmune disease patients," Cui said.

The remarks were made as the company launched a science and technology association which is dedicated to advances in the pharma industry.